[go: up one dir, main page]

DE60130100D1 - Expressions- und sekretionsvektor für menschliches interferon alpha und verfahren zur herstellung von interferon alpha durch anwendung desselben - Google Patents

Expressions- und sekretionsvektor für menschliches interferon alpha und verfahren zur herstellung von interferon alpha durch anwendung desselben

Info

Publication number
DE60130100D1
DE60130100D1 DE60130100T DE60130100T DE60130100D1 DE 60130100 D1 DE60130100 D1 DE 60130100D1 DE 60130100 T DE60130100 T DE 60130100T DE 60130100 T DE60130100 T DE 60130100T DE 60130100 D1 DE60130100 D1 DE 60130100D1
Authority
DE
Germany
Prior art keywords
interferon alpha
production
human interferon
hifnalpha
expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60130100T
Other languages
English (en)
Other versions
DE60130100T2 (de
Inventor
Se Chang Kwon
Sung Youb Jung
Ki Doo Choi
Cha Soon Kim
Sung Min Bae
Gwan Sun Lee
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hammi Holdings Co Ltd Seoul Kr
Original Assignee
Hanmi Pharmaceutical Co Ltd
Hanmi Pharmaceutical Industries Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Pharmaceutical Co Ltd, Hanmi Pharmaceutical Industries Co Ltd filed Critical Hanmi Pharmaceutical Co Ltd
Publication of DE60130100D1 publication Critical patent/DE60130100D1/de
Application granted granted Critical
Publication of DE60130100T2 publication Critical patent/DE60130100T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE60130100T 2000-01-19 2001-01-19 Expressions- und sekretionsvektor für menschliches interferon-alpha und verfahren zur herstellung von interferon-alpha durch anwendung desselben Expired - Lifetime DE60130100T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR1020000002434A KR100360594B1 (ko) 2000-01-19 2000-01-19 인간 인터페론 알파의 발현 분비벡터 및 이를 이용한인터페론 알파의 생산 방법
KR2000002434 2000-01-19
PCT/KR2001/000097 WO2001057217A1 (en) 2000-01-19 2001-01-19 Expression and secretion vector for human interferon alpha and process for producing human interferon alpha by employing same

Publications (2)

Publication Number Publication Date
DE60130100D1 true DE60130100D1 (de) 2007-10-04
DE60130100T2 DE60130100T2 (de) 2008-05-15

Family

ID=19639684

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60130100T Expired - Lifetime DE60130100T2 (de) 2000-01-19 2001-01-19 Expressions- und sekretionsvektor für menschliches interferon-alpha und verfahren zur herstellung von interferon-alpha durch anwendung desselben

Country Status (14)

Country Link
US (1) US7052867B2 (de)
EP (1) EP1250439B1 (de)
JP (1) JP3751883B2 (de)
KR (1) KR100360594B1 (de)
CN (1) CN100436581C (de)
AT (1) ATE371027T1 (de)
AU (1) AU762053B2 (de)
BR (1) BRPI0107708A8 (de)
CA (1) CA2397527C (de)
DE (1) DE60130100T2 (de)
ES (1) ES2290156T3 (de)
NZ (1) NZ520076A (de)
RU (1) RU2230116C2 (de)
WO (1) WO2001057217A1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5544063B2 (ja) * 2003-08-13 2014-07-09 サンド・アクチエンゲゼルシヤフト 組換えポリペプチドの生産のための発現ベクター、形質転換宿主細胞及び発酵方法
SI1656455T1 (sl) * 2003-08-13 2012-12-31 Sandoz Ag Postopek za čiščenje rekombinantnih polipeptidov
GB0319601D0 (en) * 2003-08-20 2003-09-24 Sandoz Ag Production process
US8110665B2 (en) 2003-11-13 2012-02-07 Hanmi Holdings Co., Ltd. Pharmaceutical composition comprising an immunoglobulin FC region as a carrier
RU2352583C2 (ru) 2003-11-13 2009-04-20 Ханми Фарм. Инд. Ко., Лтд. ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ Fc-ОБЛАСТЬ ИММУНОГЛОБУЛИНА В КАЧЕСТВЕ НОСИТЕЛЯ
RU2303063C2 (ru) * 2005-09-29 2007-07-20 ООО "Цитокин" ШТАММ Escherichia coli BL21 (DE3)[pAYC-ET-(hIFN-α2b)-IacI]-ПРОДУЦЕНТ РЕКОМБИНАНТНОГО ЧЕЛОВЕЧЕСКОГО АЛЬФА-2b ИНТЕРФЕРОНА И СПОСОБ ЕГО КУЛЬТИВИРОВАНИЯ
WO2009046080A1 (en) 2007-10-01 2009-04-09 Pharmaessentia Corp. N-terminal modified interferon-alpha
FR2964434B1 (fr) 2010-09-07 2012-08-24 Walden Associates Ltd S A Amortisseur a haut pouvoir dissipatif et pratiquement sans huile
CN103611163A (zh) 2011-09-05 2014-03-05 韩美科学株式会社 一种包含干扰素α-缀合物的抗癌用药物组合物
US11471497B1 (en) 2019-03-13 2022-10-18 David Gordon Bermudes Copper chelation therapeutics
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
US12537071B1 (en) 2020-07-22 2026-01-27 David Gordon Bermudes Bacteria having boolean control pathways expressing therapeutic proteins including immunotherapeutic cytotoxins

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3586386T2 (de) 1984-10-05 1993-01-14 Genentech Inc Dna, zellkulturen und verfahren zur sekretion von heterologen proteinen und periplasmische proteinrueckgewinnung.
JPS63230089A (ja) 1987-03-18 1988-09-26 Takeda Chem Ind Ltd 分泌発現による蛋白質の製造法
EP0626448A3 (de) * 1993-05-26 1998-01-14 BOEHRINGER INGELHEIM INTERNATIONAL GmbH Verfahren zur Herstellung und Reinigung von alpha-Interferon
US5470719A (en) * 1994-03-18 1995-11-28 Meng; Shi-Yuan Modified OmpA signal sequence for enhanced secretion of polypeptides
RU2097428C1 (ru) * 1996-12-23 1997-11-27 Государственный научный центр прикладной микробиологии Рекомбинантная плазмидная днк рттg кm2, кодирующая синтез рекомбинантного иммунного интерферона человека, штамм escherichia coli t3g - продуцент рекомбинантного иммунного интерферона человека и способ получения рекомбинантного иммунного интерферона человека
KR100316347B1 (ko) * 1998-09-15 2002-08-27 한미약품(주) 대장균엔테로톡신ⅱ신호펩티드의변형체와인체성장호르몬의융합단백질을발현하는재조합미생물및그를이용한인체성장호르몬의제조방법

Also Published As

Publication number Publication date
NZ520076A (en) 2003-07-25
JP3751883B2 (ja) 2006-03-01
JP2003521925A (ja) 2003-07-22
CN100436581C (zh) 2008-11-26
EP1250439A1 (de) 2002-10-23
CN1418251A (zh) 2003-05-14
US20040151695A1 (en) 2004-08-05
AU2890901A (en) 2001-08-14
CA2397527A1 (en) 2001-08-09
AU762053B2 (en) 2003-06-19
WO2001057217A1 (en) 2001-08-09
EP1250439A4 (de) 2004-04-07
US7052867B2 (en) 2006-05-30
KR100360594B1 (ko) 2002-11-13
ES2290156T3 (es) 2008-02-16
KR20010073658A (ko) 2001-08-01
WO2001057217A9 (en) 2002-12-27
EP1250439B1 (de) 2007-08-22
CA2397527C (en) 2010-10-19
DE60130100T2 (de) 2008-05-15
BRPI0107708A8 (pt) 2016-06-07
ATE371027T1 (de) 2007-09-15
BR0107708A (pt) 2002-11-19
RU2230116C2 (ru) 2004-06-10

Similar Documents

Publication Publication Date Title
ATE522612T1 (de) Tensid-tolerante cellulase sowie verfahren zur umwandlung davon
DE60130100D1 (de) Expressions- und sekretionsvektor für menschliches interferon alpha und verfahren zur herstellung von interferon alpha durch anwendung desselben
DE69220568D1 (de) Proteinhydrolysate aus erbse, methode zur seiner herstellung und verwendung
DE60230274D1 (de) Verfahren zur herstellung von l-aminosäuren durch enterobacteriaceae-stämmen mit verstärkter expression des pts-g
ATE80660T1 (de) Verfahren zur herstellung eines polypeptides.
NZ510385A (en) E. coli enterotoxin II signal peptide and a microorganism expressing a fusion protein of the MST peptide and a heterologous protein, such as human growth hormone
DE69941991D1 (de) Verfahren zur Herstellung von L-Aminosäure
KR850000525A (ko) 재조합 dna기법에 의한 인체 igf 및 egf제조
DE59104720D1 (de) Antifungisches polypeptid, verfahren zu seiner herstellung.
DK1194575T4 (da) Modificeret human granulocytkolonistimulerende faktor og fremgangsmåde til fremstilling heraf
PT851926E (pt) Variantes do interferao-gama (rhu-ifn-gama) recombinante humano com estabilidade termica melhorada
DE69030920D1 (de) Verfahren zur herstellung von pai-2
ATE169013T1 (de) Verfahren zur herstellung von gamma-butyrolacton
DE60219361D1 (de) Verfahren zur rekombinanten herstellung von plazenta wachstumsfaktor
DE69533626D1 (de) Tioredioxine h aus zwig und hart-weizen und ähnliche proteine, diese kodierende dna-fragmente und verfahren zu ihrer herstellung
ATE319837T1 (de) Verfahren zur herstellung von rekombinantem trypsin
DE60034941D1 (de) Essentielles material und verfahren zu dessen herstellung
ATE202798T1 (de) D-aminosäure-oxidase kodierendes dns-fragment
DE69031996D1 (de) Menschlicher rekombinanter plazentaler ribonuklease-inhibitor und verfahren zur herstellung
DE69737007D1 (de) Protein-disulfidisomerase-Gen eines methylotrophen Hefestammes
MXPA02008010A (es) Enterotoxina estafilococica sec-ser, vector de expresion y celula huesped, metodo de produccion de los mismos y metodo de fabricacion de vacuna.
DK1780275T3 (da) Polypeptid med en delta5-fedtsyre-desaturationsaktivitet, polynukleotid kodende for polypeptidet og anvendelse deraf
EP0945512A3 (de) Serinproteasen
EP1295943A4 (de) Polypeptide mit aktivität der stimulierung von neutrophilen
DE60044528D1 (de) Bazillus zelle für die herstellung von proteinen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: HAMMI HOLDINGS CO., LTD., SEOUL, KR

R082 Change of representative

Ref document number: 1250439

Country of ref document: EP

Representative=s name: UWE MANASSE, DE